| |
Tuesday, January 14, 2025 | 10am ET / 7am PT This webinar highlights the FDA’s discussion paper on health equity in medical devices, investments in inclusive product design and clinical trials, and provider programs educating patients about managing chronic conditions. Register now and discover strategies for fostering equitable access to quality care and improving outcomes for diverse populations. 
|
|
| By Gabrielle Masson Overall, biopharma layoffs rose ever so slightly in 2024 compared to the year before, though the number of layoff rounds across Big Pharma companies skyrocketed by 281%. |
|
|
|
By Fraiser Kansteiner Even as Novo and Lilly continue to climb, Roche looks poised to remain the top drugmaker by revenue in 2025, Evaluate analysts predict. |
By Andrea Park As the 2025 Hollywood awards season kicked off with the Golden Globes on Sunday night, so too did another round of jokes, speculation and sponsorships linking the industry to the use of GLP-1 medications for weight loss. |
By Gabrielle Masson Sana Biotechnology has shared early data for its investigational allogeneic cell therapy being studied in one patient with type 1 diabetes, sending the company’s stock price up by about 200%. |
|
Wednesday, January 15, 2025 | 11am ET / 8am PT Discover how next-gen Protein A resins and multi-column chromatography can help biomanufacturers optimize costs, enhance purification efficiency, and improve productivity. Learn practical strategies and explore real-world case studies showcasing advanced solutions for scalable, high-throughput processes. Register now. 
|
|
By Kevin Dunleavy The FDA will require GSK and Pfizer to include on the label of their respiratory syncytial virus (RSV) vaccines a warning about the risk of developing Guillain-Barré syndrome (GBS), a rare neurological condition that can cause paralysis. The ruling will affect GSK’s Arexvy and Pfizer’s Abrysvo. |
By James Waldron Galapagos has never been a company to sit still for long, but—even by its own standards—the decision to split in two while waving goodbye to 40% of its employees and a long-standing Gilead partnership is a bold move. |
By Conor Hale An independent review of scientific literature searched for contaminants in tampons, including not just metals but also phthalates, parabens and volatile organic compounds. |
By Nick Paul Taylor GlobalData has named heart failure as the next disease to feel the sales-boosting power of GLP-1 drugs. The analysts expect launches of medicines including Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy to help add $20 billion to the value of the market in a decade. |
By Kevin Dunleavy With the potential passage of the BIOSECURE Act looming and WuXi Biologics seeing its share price and profits decline, the Chinese biopharma contract manufacturing giant is responding with a large divestiture. |
By Darren Incorvaia British tech firm Basecamp Research is making a big push forward to further its mission of developing programmable genetic medicines. The company has hired gene therapy vet John Finn, Ph.D., to be its new chief scientific officer, working out of a new office and lab space in Cambridge, Massachusetts. |
Fierce podcasts Don’t miss an episode |
| Fierce Healthcare hosted the second annual Fierce Health Payer Summit in November. Top leaders and decision-makers in the healthcare and payer industry convened in Austin, Texas, for two days of discussions. |
|
|---|
|
|
|
Tuesday, January 21, 2025 | 11am ET / 8am PT In today’s fast-paced and uncertain landscape, pharmaceutical manufacturers face complex challenges that demand agile and integrated planning across all business functions. Join us for an exclusive webinar on how to leverage Integrated Business Planning (IBP) to enable a more connected, data-driven approach to planning. Register now. 
|
|
Whitepaper How can an emerging company attract the right partner for a therapeutic asset (& optimize its value in a transaction)? This paper offers some insights. Presented by: Blue Matter, strategic consultants in the life sciences |
Whitepaper There’s so much that goes into making sure your therapy maximizes impact every step of the way. Sponsored by: Accredo By Evernorth |
| |
|
